127 related articles for article (PubMed ID: 37748729)
1. A systematic examination of anti-drug antibody titer estimation: Applied recommendations.
Zhang L; Hodsdon ME; Pottanat T; Wang S; Konrad RJ; Seta N; Higgs RE
J Immunol Methods; 2023 Nov; 522():113569. PubMed ID: 37748729
[TBL] [Abstract][Full Text] [Related]
2. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
[TBL] [Abstract][Full Text] [Related]
3. Anti-drug Antibody Magnitude and Clinical Relevance Using Signal to Noise (S/N): Bococizumab Case Study.
McCush F; Wang E; Yunis C; Schwartz P; Baltrukonis D
AAPS J; 2023 Sep; 25(5):85. PubMed ID: 37658997
[TBL] [Abstract][Full Text] [Related]
4. Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.
Gorovits B; Wang Y; Zhu L; Araya M; Kamerud J; Lepsy C
AAPS J; 2019 Jun; 21(4):71. PubMed ID: 31161482
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.
Devanarayan V; Smith WC; Brunelle RL; Seger ME; Krug K; Bowsher RR
AAPS J; 2017 Sep; 19(5):1487-1498. PubMed ID: 28733862
[TBL] [Abstract][Full Text] [Related]
6. Non-normal random effects models for immunogenicity assay cut point determination.
Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
[TBL] [Abstract][Full Text] [Related]
7. Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact.
Tatarewicz SM; Mytych DT; Manning MS; Swanson SJ; Moxness MS; Chirmule N
Bioanalysis; 2014 Jun; 6(11):1509-23. PubMed ID: 25046051
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium.
Starcevic Manning M; Hassanein M; Partridge MA; Jawa V; Mora J; Ryman J; Barker B; Braithwaite C; Carleton K; Hay L; Hottenstein C; Kubiak RJ; Devanarayan V
AAPS J; 2022 Jul; 24(4):81. PubMed ID: 35821280
[TBL] [Abstract][Full Text] [Related]
9. The Immunogenicity of Biologic Therapies.
Garcês S; Demengeot J
Curr Probl Dermatol; 2018; 53():37-48. PubMed ID: 29131036
[TBL] [Abstract][Full Text] [Related]
10. Neutralization Activity of Anti-drug Antibodies Against a Biotherapeutic Can Be Predicted from a Comprehensive Pharmacokinetics, Pharmacodynamics, and Anti-drug Antibody Data Analysis.
Xu W; Maas B; Roadcap B; Swarup A; Steinmetz T; Luo L; Ichetovkin M; Wood S; Vazvaei-Smith F; Lee AW; Vora K; Helmy R
AAPS J; 2022 Sep; 24(6):102. PubMed ID: 36167856
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan.
Ishii-Watabe A; Shibata H; Nishimura K; Hosogi J; Aoyama M; Nishimiya K; Saito Y
Bioanalysis; 2018 Jan; 10(2):95-105. PubMed ID: 29243491
[TBL] [Abstract][Full Text] [Related]
12. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
Nishimura K; Shibata H; Aoyama M; Hosogi J; Kadotsuji K; Minoura K; Mori T; Nakamura T; Nishimiya K; Nomura T; Saito T; Soma M; Wakabayashi H; Sakamoto N; Niimi S; Katori N; Saito Y; Ishii-Watabe A
Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
[No Abstract] [Full Text] [Related]
13. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
[TBL] [Abstract][Full Text] [Related]
14. Statistical approaches for the determination of cut points in anti-drug antibody bioassays.
Schaarschmidt F; Hofmann M; Jaki T; Grün B; Hothorn LA
J Immunol Methods; 2015 Mar; 418():84-100. PubMed ID: 25733352
[TBL] [Abstract][Full Text] [Related]
15. A survey of applications of biological products for drug interference of immunogenicity assays.
Wang YM; Fang L; Zhou L; Wang J; Ahn HY
Pharm Res; 2012 Dec; 29(12):3384-92. PubMed ID: 22903525
[TBL] [Abstract][Full Text] [Related]
16. Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies.
Bharadwaj P; Riekofski C; Lin S; Seaman MS; Garber DA; Montefiori D; Sarzotti-Kelsoe M; Ackerman ME; Weiner JA
J Immunol Methods; 2020 Apr; 479():112764. PubMed ID: 32070674
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.
Ponce-Bobadilla AV; Stodtmann S; Chen MJ; Winzenborg I; Mensing S; Blaes J; Haslberger T; Laplanche L; Dreher I; Mostafa NM
Clin Pharmacokinet; 2023 Apr; 62(4):623-634. PubMed ID: 36905528
[TBL] [Abstract][Full Text] [Related]
18. A new method for identification of outliers in immunogenicity assay cut point data.
Zhang J; Arends RH; Kubiak RJ; Roskos LK; Liang M; Lee N; Chen CC; Yang H
J Immunol Methods; 2020; 484-485():112817. PubMed ID: 32615125
[TBL] [Abstract][Full Text] [Related]
19. Enhancing efficiency and quality of statistical estimation of immunogenicity assay cut points through standardization and automation.
Su C; Zhou L; Hu Z; Weng W; Subramani J; Tadkod V; Hamilton K; Bautista A; Wu Y; Chirmule N; Zhong ZD
J Immunol Methods; 2015 Oct; 425():88-96. PubMed ID: 26130368
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of singlicate-based analysis in bridging ADA assay on Meso-Scale Discovery platform: comparison with duplicate analysis.
Jiang Z; Kamerud J; You Z; Basak S; Seletskaia E; Steeno GS; Gorovits B
Bioanalysis; 2021 Jul; 13(14):1123-1134. PubMed ID: 34275328
[No Abstract] [Full Text] [Related]
[Next] [New Search]
